CoImmune, an immuno-oncology therapy company, completed the merger with Formula Pharmaceuticals, a biopharmaceutical company. Financial terms were not disclosed. "We are excited about bringing together two therapeutic immuno-oncology platforms to maximize our clinical and commercial value. We believe that both companies complement each other, and together, this relationship will enable us to continue to advance our therapies toward US FDA approval in the near future," Charles Nicolette, CoImmune Chief Executive Officer.